On April 18, 2022 Brand Institute reported its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed (Press release, Amneal Pharmaceuticals, APR 18, 2022, View Source [SID1234612415]). This biosimilar represents the third bevacizumab approved in the U.S.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALYMSYS was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. Bevacizumab-maly is a vascular endothelial growth factor inhibitor used in oncology.

"The entire Brand Institute and Drug Safety Institute Team congratulates Amneal Pharmaceuticals and mAbxience on the FDA approval of ALYMSYS," said Brand Institute’s Chairman and C.E.O., James L. Dettore.